These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 18941125)

  • 1. The outcome of prostate cancer screening in a normal Japanese population with PSA of 2-4 ng/ml and the free/total PSA under 12%.
    Ishidoya S; Ito A; Orikasa K; Kawamura S; Tochigi T; Kuwahara M; Yamanobe T; Tomita Y; Masumori N; Tsukamoto T; Shibuya D; Arai Y
    Jpn J Clin Oncol; 2008 Dec; 38(12):844-8. PubMed ID: 18941125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical utility of the prostate cancer gene 3 (PCA3) urine assay in Japanese men undergoing prostate biopsy.
    Ochiai A; Okihara K; Kamoi K; Oikawa T; Shimazui T; Murayama S; Tomita K; Umekawa T; Uemura H; Miki T
    BJU Int; 2013 May; 111(6):928-33. PubMed ID: 23331404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of prostate cancer in men with prostate-specific antigen levels of 2.0 to 4.0 ng/mL equivalent to that in men with 4.1 to 10.0 ng/mL in a Japanese population.
    Kobayashi T; Nishizawa K; Ogura K; Mitsumori K; Ide Y
    Urology; 2004 Apr; 63(4):727-31. PubMed ID: 15072889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer screening in Tyrol, Austria: experience and results.
    Horninger W; Reissigl A; Rogatsch H; Volgger H; Studen M; Klocker H; Bartsch G
    Eur Urol; 1999; 35(5-6):523-38. PubMed ID: 10325519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination.
    Uzzo RG; Pinover WH; Horwitz EM; Parlanti A; Mazzoni S; Raysor S; Mirchandani I; Greenberg RE; Pollack A; Hanks GE; Watkins-Bruner D
    Urology; 2003 Apr; 61(4):754-9. PubMed ID: 12670560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.
    Catalona WJ; Smith DS; Ornstein DK
    JAMA; 1997 May; 277(18):1452-5. PubMed ID: 9145717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination.
    Schröder FH; Roobol-Bouts M; Vis AN; van der Kwast T; Kranse R
    Urology; 2001 Jan; 57(1):83-90. PubMed ID: 11164149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The significance of early detection for prostate cancer in mass screening].
    Kato M; Tammbo M; Yoshimatsu T; Ohta M; Kinjyo M; Noda H; Watanabe K; Miyata A; Murata A; Miura I; Yoneda T; Yoshii M; Okegawa T; Kojima M; Sayama T; Nutahara K; Higashihara E
    Nihon Hinyokika Gakkai Zasshi; 2001 Jan; 92(1):23-9. PubMed ID: 11235139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen.
    Catalona WJ; Bartsch G; Rittenhouse HG; Evans CL; Linton HJ; Horninger W; Klocker H; Mikolajczyk SD
    J Urol; 2004 Jun; 171(6 Pt 1):2239-44. PubMed ID: 15126794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate cancer screening in the Tyrol, Austria: experience and results.
    Horninger W; Reissigl A; Rogatsch H; Volgger H; Studen M; Klocker H; Bartsch G
    Eur J Cancer; 2000 Jun; 36(10):1322-35. PubMed ID: 10882875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
    Haese A; Dworschack RT; Partin AW
    J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of the percentage of free prostate-specific antigen helps to avoid unnecessary biopsies in men with normal rectal examinations and total prostate-specific antigen of 4-10 ng/ml.
    Martínez-Piñeiro L; Tabernero A; Contreras T; Madero R; Lozano D; López-Tello J; Alonso-Dorrego JM; Picazo ML; González Gancedo P; Martínez-Piñeiro JA; de La Peña JJ
    Eur Urol; 2000 Mar; 37(3):289-96. PubMed ID: 10720854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective validation of %p2PSA and the Prostate Health Index, in prostate cancer detection in initial prostate biopsies of Asian men, with total PSA 4-10 ng ml-1.
    Tan LG; Tan YK; Tai BC; Tan KM; Gauhar V; Tiong HY; Hawkins RC; Thamboo TP; Hong FS; Chiong E
    Asian J Androl; 2017; 19(3):286-290. PubMed ID: 26908062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening.
    Catalona WJ; Smith DS; Wolfert RL; Wang TJ; Rittenhouse HG; Ratliff TL; Nadler RB
    JAMA; 1995 Oct; 274(15):1214-20. PubMed ID: 7563511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of 2.6 ng/ml prostate specific antigen prompt for biopsy in men older than 60 years.
    Nadler RB; Loeb S; Roehl KA; Antenor JA; Eggener S; Catalona WJ
    J Urol; 2005 Dec; 174(6):2154-7, discussion 2157. PubMed ID: 16280754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Percent free prostate-specific antigen is effective to predict prostate biopsy outcome in Chinese men with prostate-specific antigen between 10.1 and 20.0 ng ml(-1).
    Chen R; Zhou LQ; Cai XB; Xie LP; Huang YR; He DL; Gao X; Xu CL; Ding Q; Wei Q; Yin CJ; Ren SC; Wang FB; Tian Y; Sun ZQ; Fu Q; Ma LL; Zheng JH; Ye ZQ; Ye DW; Xu DF; Hou JQ; Xu KX; Yuan JL; Gao X; Liu CX; Pan TJ; Sun YH;
    Asian J Androl; 2015; 17(6):1017-21. PubMed ID: 25926603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate carcinoma screening in the county of Tyrol, Austria: experience and results.
    Reissigl A; Horninger W; Fink K; Klocker H; Bartsch G
    Cancer; 1997 Nov; 80(9):1818-29. PubMed ID: 9351555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
    Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
    BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
    Mäkinen T; Tammela TL; Hakama M; Stenman UH; Rannikko S; Aro J; Juusela H; Määttänen L; Auvinen A
    J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age and PSA predict likelihood of organ-confined disease in men presenting with PSA less than 10 ng/mL: implications for screening.
    Aleman M; Karakiewicz PI; Kupelian P; Kattan MW; Graefen M; Cagiannos I; Eastham J; Scardino PT; Huland H; Klein EA
    Urology; 2003 Jul; 62(1):70-4. PubMed ID: 12837425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.